Keywords: AstraZeneca, Arimidex, Breast cancer, Patient program, USA

AstraZeneca offering Arimidex for just $40 a month in USA

Article | 16 February 2012

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has launched what it says is its first-ever direct-to-patient program offering those with a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in